Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data -

Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
Information type: Other primary research
Source: The Lancet Haematology
Specialities: Cardiovascular system disorders | Haematological disorders | Nutritional and metabolic disorders
Summary
Retrospective analysis of data evaluating safety and efficacy of direct oral anticoagulants and warfarin in 795 morbidly obese patients (BMI>40kg/m2) suggests concludes similar efficacy and safety of apixaban and rivaroxaban, compared to warfarin in patients with AF and VTE.
UKMi comment
A related editorial discusses the findings of this study. Manufacturers of both rivaroxaban and apixaban do not suggest dose adjustment for extremes of body weight.
Related links: Editorial